Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. NextCure, Inc.
  6. Company
    NXTC   US65343E1082

NEXTCURE, INC.

(NXTC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo NextCure, Inc.
Nextcure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its product candidates include NC318, NC410, and NC762. Its lead product candidate NC318, is an immunomedicine targeting a immunomodulatory receptor called Siglec-15 (S15). The Company is evaluating NC318 for the treatment of metastatic solid tumors, including head and neck squamous cell carcinoma (HNSCC) and triple-negative breast cancer (TNBC). It is conducting Phase II investigator-initiated clinical trial of NC318 in combination with pembrolizumab in patients with non-small cell lung cancer (NSCLC). Its second product candidate NC410, is an immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor1. Its NC762, is a monoclonal antibody targeting an immunomodulatory molecule called human B7 homolog 4 protein (B7-H4).

Number of employees : 90 people.
Managers
Name Title Age Since
Michael S. Richman President, Chief Executive Officer & Director 60 2015
Steven P. Cobourn Chief Financial Officer 58 2018
Solomon Langermann, Dr. Senior Vice President-Research 61 2015
Linda N. Liu, Dr. Senior Vice President-Research 54 2018
Han Myint, Dr. Chief Medical Officer 68 2021
Timothy Mayer, Dr. Vice President-Business Development 56 2016
Chau Quang Khuong Independent Director 45 2015
Elaine V. Jones, Dr. Independent Director 66 2015
David S. Kabakoff, Dr. Chairman 73 2015
Stephen W. Webster Independent Director 60 2019
Members of the board
Name Title Age Since
David S. Kabakoff, Dr. Chairman 73 2015
Michael S. Richman President, Chief Executive Officer & Director 60 2015
Chau Quang Khuong Independent Director 45 2015
Elaine V. Jones, Dr. Independent Director 66 2015
Stephen W. Webster Independent Director 60 2019
Garry Allen Nicholson Independent Director 66 2020
John Houston Independent Director 61 2020
Ellen G. Feigal, Dr. Independent Director 66 2021
Anne Borgman Hagey, Dr. Independent Director 52 2021
Shareholders
NameEquities%
OrbiMed Advisors Private Equity 2,711,013 9.82%
Sofinnova Investments, Inc. 2,671,856 9.68%
Eli Lilly and Company 2,088,859 7.57%
Pfizer Inc. 1,970,759 7.14%
Lord, Abbett & Co. LLC 1,764,147 6.39%
Quan Capital Management LLC 1,103,570 4.00%
Great Point Partners LLC 999,666 3.62%
Hillhouse Investment Management Ltd. (Hong Kong) 978,570 3.54%
The Vanguard Group, Inc. 798,252 2.89%
SilverArc Capital Management LLC 721,302 2.61%
Company contact information
NextCure, Inc.
9000 Virginia Manor Road
Suite 200
Beltsville, MD 20705

Phone : +1.240.399.4900
Web : http://www.nextcure.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of NextCure, Inc.
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
NEXTCURE, INC.-15.50%140
GILEAD SCIENCES, INC.-5.19%86 352
REGENERON PHARMACEUTICALS-4.49%63 067
VERTEX PHARMACEUTICALS3.42%57 743
WUXI APPTEC CO., LTD.-7.49%50 700
BIONTECH SE-39.30%37 796
BEIGENE, LTD.-13.83%23 988
GENMAB A/S-19.05%21 110
ARGENX SE-27.53%13 318
ACCELERON PHARMA INC.39.71%10 932
HUALAN BIOLOGICAL ENGINEERING INC.-10.71%7 504
NEUROCRINE BIOSCIENCES, INC.-10.85%7 203
GW PHARMACEUTICALS PLC89.72%6 907
ASCENDIS PHARMA A/S-15.57%6 453
MIRATI THERAPEUTICS, INC.-22.26%6 297
SAREPTA THERAPEUTICS, INC.-23.70%5 983
BIOCON LIMITED2.65%5 955
LEGEND BIOTECH CORPORATION-18.22%5 868
EXELIXIS, INC.1.31%5 762
ARROWHEAD PHARMACEUTICALS, INC.-23.09%5 330
HALOZYME THERAPEUTICS, INC.-13.70%4 719